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OBJECTIVE—Fibroblast growth factor 21 (FGF21) has
emerged as an important metabolic regulator of glucose and lipid
metabolism. The aims of the current study are to evaluate the
role of FGF21 in energy metabolism and to provide mechanistic
insights into its glucose and lipid-lowering effects in a high-fat
diet–induced obesity (DIO) model.
RESEARCH DESIGN AND METHODS—DIO or normal lean
mice were treated with vehicle or recombinant murine FGF21.
Metabolic parameters including body weight, glucose, and lipid
levels were monitored, and hepatic gene expression was ana-
lyzed. Energy metabolism and insulin sensitivity were assessed
using indirect calorimetry and hyperinsulinemic-euglycemic
clamp techniques.
RESULTS—FGF21 dose dependently reduced body weight and
whole-body fat mass in DIO mice due to marked increases in
total energy expenditure and physical activity levels. FGF21 also
reduced blood glucose, insulin, and lipid levels and reversed
hepatic steatosis. The profound reduction of hepatic triglyceride
levels was associated with FGF21 inhibition of nuclear sterol
regulatory element binding protein-1 and the expression of a
wide array of genes involved in fatty acid and triglyceride
synthesis. FGF21 also dramatically improved hepatic and periph-
eral insulin sensitivity in both lean and DIO mice independently
of reduction in body weight and adiposity.
CONCLUSIONS—FGF21 corrects multiple metabolic disorders
in DIO mice and has the potential to become a powerful
therapeutic to treat hepatic steatosis, obesity, and type 2 diabe-
tes. Diabetes 58:250–259, 2009
F
ibroblast growth factor (FGF) 21 is a member of
the FGF superfamily (1). It is most closely re-
lated to FGF19 and FGF23, sharing 30–35%
amino acid sequence homology (1). The FGF19
subfamily comprises FGF19, FGF21, and FGF23 (2), and
all three FGF19 subfamily members have recently
emerged as metabolic hormones involved in the regulation
of glucose, lipid, bile acid, and phosphate metabolism
(2–6).
FGF21 was isolated from a mouse embryo cDNA
library and appeared as an atypical FGF preferentially
expressed in tissues related with metabolic functions,
such as liver (7) and pancreas (J.X., S. Sheila, unpub-
lished data). A biological activity of FGF21 was revealed
in a high-throughput assay looking for secreted proteins
that stimulate glucose uptake in 3T3-L1 adipocytes (5).
Further studies demonstrated that FGF21 increased the
expression of GLUT1 and stimulated GLUT1-mediated
glucose uptake in differentiated adipocytes (5). When
recombinant FGF21 protein was administered to ob/ob
and db/db mice and Zucker fatty rats, which are rodent
models of diabetes, it lowered blood glucose and trig-
lycerides to near-normal levels (5). In diabetic rhesus
monkeys, treatment also resulted in a favorable lipopro-
tein proﬁle, which included reduced LDL cholesterol
and increased HDL cholesterol (8). Furthermore, trans-
genic mice with hepatic overexpression of FGF21 were
lean and protected from high-fat diet–induced insulin
resistance (5,9).
Recent progress has also been made in elucidating the
receptor signaling complex and cellular functions of
FGF21. In vitro studies suggest that FGF21 initiates its
action by activating a unique dual receptor complex
consisting of a coreceptor -klotho and the tyrosine kinase
FGF receptors (FGFRs) (10–12). -klotho binds FGF21
and facilitates its activation of FGFRs (11,12). -klotho is
predominantly expressed in metabolic organs, including
liver, adipose tissue, and pancreas (13), and may deﬁne the
in vivo sites where FGF21 acts. FGF21 has been shown to
stimulate glucose uptake in adipocytes (5) and to inhibit
glucagon secretion and preserve insulin content in pancre-
atic islets (5,14). Additionally, FGF21 has also been shown
to enhance hepatic lipid oxidation and ketone body pro-
duction (9,15).
The metabolic effects of FGF21 have been previously
evaluated by other groups using monogenic leptin-deﬁ-
cient and age-related spontaneous insulin-resistant models
(5,8). We conducted our studies using a high-fat diet–
induced obesity (DIO) model, because the metabolic char-
acteristics of DIO more closely resemble those of human
type 2 diabetes and could therefore provide a broader
measure of the various associated metabolic parameters.
In this report, our objective was to evaluate the role of
FGF21 in energy metabolism and to provide mechanistic
insights into its underlying glucose and lipid-lowering
effects.
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Preparation of recombinant FGF21. Recombinant murine FGF21 (amino
acids 30–210) was expressed in Escherichia coli. It was folded in solubilized
inclusion bodies and puriﬁed by ion exchange and hydrophobic interaction
chromatography to obtain 90% purity.
Animals and treatments. Male C57BL/6 mice were obtained from Charles
Rivers Laboratories (Wilmington, MA) at 3 weeks of age. After 12 weeks of a
diet period, either a standard diet (8640; Harlan Teklad, Indianapolis, IN) or a
high-fat diet (D12492, Research Diets, New Brunswick, NJ), mice were
randomly assigned to treatment or vehicle groups, and the randomization was
stratiﬁed by body weight and fed blood glucose levels. The mice were
intraperitonally injected with vehicle or FGF21 twice daily (at one-half of the
daily dose) to achieve the indicated daily dose for each of the experiments
performed. Mice were maintained on their respective diets during the drug
treatment periods. All experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) at Amgen.
Metabolic effects. In a 6-week pharmacological study, FGF21 was adminis-
trated to DIO mice at 0 (vehicle), 0.1, 1, and 10 mg  kg
1  day
1. A group of
DIO mice was treated with rosiglitazone formulated in the high-fat diet at 50
mg/kg diet to provide a dose of 4m g kg
1  day
1. Body weight was
recorded every other day, and food intake was measured every 6 days
throughout the study. At day 24, blood was collected from the retro-orbital
sinus of each nonanesthetized mouse to measure blood glucose, insulin,
glucagon, leptin, triglyceride, cholesterol, free fatty acids, aspartate amino-
transaminase (AST), alanine aminotransaminase (ALT), and alkaline phospha-
tase (ALP) levels. Body composition was analyzed on day 27 using an
EchoMRI-100 analyzer (Echo Medical Systems, Houston, TX). A glucose
tolerance test (GTT) was performed on day 30 with an intraperitonal injection
of a 2 mg/kg glucose solution after a 12-h fast. Terminal decapitated trunk
blood was collected to measure -hydroxybutyrate. Tissues were collected
for lipid analysis, mRNA and protein expression analysis, and histological
examinations.
Analysis of endocrine hormones and metabolites. Plasma insulin, gluca-
gon, and leptin were measured with a mouse endocrine multiplex assay (Linco
Research, St. Charles, MO). Blood glucose was measured with a OneTouch
Glucometer (LifeScan, Milpitas, CA). Plasma cholesterol, triglyceride, nones-
teriﬁed fatty acids, AST, ALT, and ALP were measured using an Olympus
AU400e Chemistry Analyzer (Olympus America, Center Valley, PA). Plasma
-hydroxybutyrate concentration was measured using D-3-hydroxybutyric
acid colorimetric method (R-Biopharm, Marshall, MI). Hepatic and muscle
lipid extraction was conducted as described previously (16,17), and lipid
contents were measured with a triglyceride kit (TR0100; Sigma-Aldrich, St.
Louis, MO) and a cholesterol kit (Boehringer Mannheim, Ridgeﬁeld, CT).
Quantitative real-time PCR and Western analysis. RNA was isolated from
liver samples using the RNeasy kit (Qiagen, Valencia, CA). The reactions were
carried out with 100 ng total RNA using TaqMan One Step PCR kit with
6-carboxy-ﬂuorescein (FAM) dye-labeled TaqMan chemistry (Applied Biosys-
tems, Foster City, CA). Cyclophilin A was used as the internal standard.
Relative gene expression was analyzed using an ABI 7900 sequence detection
system. Western blot analyses were performed using total protein extracted
from frozen liver samples using radioimmunoprecipitation assay lysis buffer
containing protease inhibitors. The following primary antibodies were used:
monoclonal anti–sterol regulatory element binding protein-1 (anti-SREBP1;
IgG-2A4) prepared from hybridoma cells (CRL 2121; American Type Culture
Collection); rabbit polyclonal anti–peroxisome proliferator–activated recep-
tor  (anti-PPAR) (2435; Cell Signaling); monoclonal anti–fatty acid synthase
(anti-FAS) antibody (610962; BD Biosciences); and monoclonal anti–-actin
(ACTB12-M; Alpha Diagnostic). Total acetyl-CoA carboxylase (ACC) was
probed with streptavidin-horseradish peroxidase (E34; Biomeda) as described
previously (18).
Histology. Tissues were ﬁxed in 10% zinc-formalin. Tissues were processed,
embedded in parafﬁn, sectioned at a thickness of 5 m, and stained with
hematoxylin-eosin (H-E). For oil-red-O staining, livers were snap-frozen in
isopentane cooled in liquid nitrogen, embedded in optimum cutting tempera-
ture, and sectioned on a cryostat.
Indirect calorimetry. Recombinant FGF21 was administered to DIO mice at
1 and 10 mg  kg
1  day
1 divided into two daily injections for a period of 19
days. Metabolic rate was assessed using the Comprehensive Laboratory
Animal Monitoring System (Columbus Instruments, Columbus, OH). Data on
O2 consumption (Vo2; milliliters per hour per mouse), CO2 production (Vco2;
milliliters per hour per mouse), and activity (beam breaks) were collected
every 20 min for the entire 19 days. Respiratory quotient was derived from the
ratio of Vo2 to Vco2, and energy expenditure was calculated as follows: Energy
expenditure  (3.815  1.232 	 respiratory quotient) 	 Vo2. Daily body
weight and food intake were manually measured.
Hyperinsulinemic-euglycemic clamp. This study was performed at the
Pennsylvania State Diabetes & Obesity Mouse Phenotyping Center and
approved by Pennsylvania State University IACUC. Brieﬂy, mice were fed
standard diet or high-fat diet for 15 weeks and treated with FGF21 or vehicle
during the last 3 weeks of the diet period. One group of mice fed standard diet
was administered a 10 mg  kg
1  day
1 dose of FGF21, and two groups of DIO
mice were administered 0.1 and 10 mg  kg
1  day
1 doses of FGF21. After an
overnight fast, a 2-h hyperinsulinemic-euglycemic clamp was conducted as
previously described (19). Basal and insulin-stimulated whole-body glucose
turnover were estimated using a continuous infusion of [3-
3H]glucose
(PerkinElmer, Boston, MA) for 2 h before the clamps (0.05 Ci/min) and
throughout the clamps (0.1 Ci/min), respectively. Whole-body glycogen plus
lipid synthesis is calculated as the difference between whole-body glucose
turnover and glycolysis. To estimate insulin-stimulated glucose uptake in
individual tissues, 2-deoxy-D-[1-
14C]glucose (2-[
14C]DG; PerkinElmer) was
administered (10 Ci) 75 min after the start of the clamps. Blood samples
were taken before, during, and at the end of clamps for measurement of
plasma [
3H]glucose,
3H2O, 2-[
14C]DG concentrations, and/or insulin concen-
trations. At the end of the clamp, tissues (gastrocnemius, tibialis anterior,
quadriceps, white and brown adipose, liver, and heart) were taken for
biochemical analysis as previously described (19).
Statistical analysis. Data are presented as means 
 SE. Statistical compar-
ison of the means among the groups was made using one-way ANOVA.
Differences between the means of individual groups were analyzed by the post
hoc Fisher’s test using Statview software (SAS Institute, Cary, NC).
RESULTS
Recombinant FGF21 reduces body weight and adiposity.
Figure 1A shows representative mice fed either standard
diet or high-fat diet treated with vehicle, 10 mg  kg
1 
day
1 FGF21, or rosiglitazone (4m g kg
1  day
1) for 6
weeks. Compared with age-matched mice on standard
diet, mice on high-fat diet were markedly heavier with
elevated body fat mass (Fig. 1A–C). Treatment with
FGF21 (1 and 10 mg  kg
1  day
1) reduced body weight
by 8 and 22% at the end of 6 weeks of study (Fig. 1B) and
was associated with 15 and 36% reductions in body fat
mass, respectively (Fig. 1C). Marginal but statistically
signiﬁcant decreases in lean mass were also observed
based on body composition analysis (Fig. 1C). Throughout
the treatment period, DIO mice treated with the lowest
dose of FGF21 (0.1 mg  kg
1  day
1) had relatively stable
body weights (Fig. 1B), which were not signiﬁcantly
different from those of vehicle-treated DIO mice (6 vs. 8%
body weight gain from baseline, 50.2 
 0.7 vs. 51.4 
 0.9 g
at the end of study; treated vs. vehicle). FGF21 treatment
did not reduce the amount of daily food intake in DIO mice
(Fig. 1D). Considering the reduced body weight, mice
treated with FGF21 appeared hyperphagic.
Recombinant FGF21 improves glucose and lipid
homeostasis. Administration of FGF21 resulted in a dose-
dependent reduction in circulating levels of glucose, insu-
lin, cholesterol, triglycerides, free fatty acids, and leptin
(Fig. 2A–E). There were no signiﬁcant changes in plasma
glucagon levels (Table 1). Plasma -hydroxybutyrate was
statistically signiﬁcantly reduced after 6 weeks of FGF21
treatment (1 and 10 mg  kg
1  day
1) (Table 1). A GTT
was performed on study day 30 (Fig. 2F) after a 12-h fast.
At time 0, the fasting blood glucose levels of FGF21-
treated DIO mice were signiﬁcantly lower than those of
vehicle-treated DIO mice and approached levels typically
found in normal lean mice. The glucose excursions after
the glucose challenge were dose dependently improved by
FGF21 treatment. It is worth noting that the lowest dose
(0.1 mg  kg
1  day
1) of FGF21 reduced plasma glucose,
insulin, and lipid levels (Fig. 2A–D) and restored glucose
tolerance as effectively as rosiglitazone (Fig. 2F) in the
absence of reduction in body weight (Fig. 1B), body fat
content (Fig. 1C), or plasma leptin (Fig. 2E) levels.
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decreases tissue lipid contents in DIO mice. Histolog-
ical examination of liver sections stained with H-E (Fig.
3A–D) and oil-red-O (Fig. 3E–H) showed that there was
extensive micro- and macrovesicular hepatocyte vacuola-
tion (Fig. 3B), reﬂecting intrahepatic fat accumulation
(Fig. 3F) in vehicle-treated DIO mice. In contrast, hepato-
cellular vacuolation and intense oil-red-O–stained lipid
droplets were not observed in liver sections from FGF21-
treated DIO mice (Fig. 3C and G). Biochemical analysis
showed marked reductions of hepatic triglyceride and
cholesterol content (Table 1) in livers of FGF21-treated
DIO mice, accompanied by reductions of plasma AST,
ALT, and ALP levels (Table 1). Treatment with rosiglita-
zone did not improve the steatotic state (Fig. 3D and H;
Table 1). Muscle triglyceride content was decreased in
DIO mice treated with 10 mg/kg FGF21 (Table 1). Muscle
cholesterol content was also reduced after FGF21 treat-
ment; however, this reduction was not statistically signif-
icant (Table 1). Histological examination of brown adipose
tissue sections (Fig. 3I–L) also showed reduced lipid
accumulation in FGF21-treated DIO mice (Fig. 3K) com-
pared with vehicle-treated mice (Fig. 3J). No signiﬁcant
histological changes were observed with respect to the
pancreatic islets (Fig. 3M–P).
FGF21 inhibits hepatic lipogenic, adipogenic, and
glucose production pathways. Hepatic lipid metabolism
was studied to understand the molecular mechanisms
underlying FGF21 reduction of hepatic steatosis. We
found that expression levels of multiple genes involved in
fatty acid oxidation or uncoupling were upregulated
in mice fed high-fat diet compared with expression lev-
els in mice fed standard diet (supplementary Fig. 1B,
available in an online appendix at http://dx.doi.org/10.
2337/db08-0392), indicating an increased requirement for
fatty acid oxidation during high-fat diet feeding. Treatment
with FGF21 did not further increase the expression of fatty
acid oxidative genes (supplementary Fig. 1B). In contrast,
FGF21 dose dependently reduced the amount of the
nuclear form of SREBP-1 without changing the amount of
the membrane precursor or its mRNA (Fig. 4A and C). A
cluster of SREBP-1 target genes involved in hepatic glyco-
lysis and de novo fatty acid and triglyceride biosynthesis
were also downregulated after FGF21 treatment (Fig. 4C).
The enzyme levels of ACC and FAS were also reduced
(Fig. 4B). The expression of PPAR and its target genes
adipocyte fatty acid binding protein-2 (aP2) and CD36
were elevated in the livers of DIO mice and reduced after
FGF21 treatment (Fig. 4B and D). On the other hand, the
PPAR ligand rosiglitazone dramatically increased hepatic
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FIG. 1. Reversal of high-fat diet–induced obesity by recombinant FGF21 in DIO mice. DIO mice were treated with recombinant murine FGF21
intraperitonally at doses of 0 (vehicle), 0.1, 1, or 10 mg  kg
1  day
1 divided into two daily injections. An additional group of DIO mice was treated
with rosiglitazone formulated in the high-fat diet to provide a dose of 4m g kg
1  day
1. Mice on standard diet (SD) were included as controls
and injected intraperitonally with vehicle. A: Photograph of representative mice either fed standard diet and administered vehicle or fed high-fat
diet and administered vehicle, 10 mg  kg
1  day
1 FGF21, or rosiglitazone for 6 weeks. B: Body weight monitored throughout the treatment. C:
Body composition analyzed after 27 days of treatment. D: Average daily food intake during 6 weeks of treatment. Vehicle (open circles or open
bars); FGF21 (open triangles or striped bars; 0.1, 1, and 10 denote FGF21 doses in mg  kg
1  day
1); rosiglitazone (black squares or black bars).
All data are means  SE, n  10 per group, P < 0.05; #P < 0.01; *P < 0.001 vs. vehicle-treated high-fat diet mice. (Please see
http://dx.doi.org/10.2337/db08-0392 for a high-quality digital representation of this ﬁgure.)
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252 DIABETES, VOL. 58, JANUARY 2009aP2 and CD36 expression (Fig. 4D). FGF21 also reduced
the mRNA expression levels of glucose-6-phosphatase
without affecting PEPCK (Fig. 4E), suggesting that FGF21
may inhibit glucose release from glycogenolysis.
Recombinant FGF21 increases energy expenditure
and physical activity. Treatment with FGF21 reduced
body weight without altering food intake in DIO mice,
suggesting alterations in energy metabolism. We per-
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FIG. 2. Recombinant FGF21 reduces plasma glucose, insulin, and lipid levels and improves glucose tolerance in DIO mice. Mice were treated with
vehicle or recombinant murine FGF21 intraperitonally at doses of 0 (vehicle), 0.1, 1, or 10 mg  kg
1  day
1 divided into two daily injections (8:00
A.M. and 4:00 P.M.). Mice were fed ad libitum, and blood was collected 1 h after the morning injection on study day 24. A: Blood glucose. B: Plasma
insulin. C: Plasma cholesterol and triglyceride levels. D: Plasma nonesteriﬁed free fatty acid (NFFA) levels. E: Plasma leptin. F: GTT was initiated
1 h after the morning injection on study day 30. Fasted mice were intraperitonally injected with 2 mg/kg glucose solution, and blood glucose was
measured at 0 min (before glucose injection) and at 30 and 90 min (after glucose injection). Vehicle (open circles or open bars); FGF21 (open
triangles or striped bars; 0.1, 1, and 10 denote FGF21 doses in mg  kg
1  day
1); rosiglitazone (black squares or black bars). All data are means 
SE, n  10 per group, P < 0.05; #P < 0.01; *P < 0.001 vs. vehicle-treated high-fat diet mice. NEFA, nonesteriﬁed fatty acid.
TABLE 1
Liver and plasma metabolic parameters in mice fed standard diet or high-fat diet and treated with vehicle, FGF21, and rosiglitazone
Parameters
Standard
diet High-fat diet
Vehicle Vehicle
FGF21
Rosiglitazone 0.1 mg/kg 1 mg/kg 10 mg/kg
Body weight (g)* 32.6 
 1.2† 49.1 
 0.8 51.2 
 0.9 46.1 
 1.1 38.0 
 1.0† 56.2 
 2.1†
Liver weight (g)* 1.5 
 0.1† 2.5 
 0.2 1.9 
 0.2 1.5 
 0.11† 1.2 
 0.5† 2.9 
 0.14
Liver triglyceride (mg/g)* 10 
 2.5† 154 
 13.4 103 
 27.5‡ 47 
 2.5† 23 
 1.5† 212 
 6.6§
Liver cholesterol (mg/g)* 1.6 
 0.1† 6.4 
 1.0 4.1 
 1.0‡ 1.6 
 0.1† 1.7 
 0.1† 6.7 
 0.5
Gastrocnemic muscle weight (g)* 0.36 
 0.01 0.38 
 0.02 0.39 
 0.01 0.37 
 0.01 0.35 
 0.01 0.37 
 0.01
Muscle triglyceride (mg/g)* 16 
 1.7† 65 
 6.6 64 
 11 60 
 7.5 37 
 4.6‡ 90 
 15
Muscle cholesterol (mg/g)* 1.1 
 0.06 1.7 
 0.4 1.7 
 0.4 1.3 
 0.07 1.1 
 0.05 2.1 
 0.4
Plasma ALT (units/l)¶ 25 
 2.6† 248 
 69.7 82 
 16.6§ 44 
 4.5† 30 
 5.4† 142 
 32.7‡
Plasma AST (units/l)¶ 49 
 4.6† 205 
 48 102 
 17§ 81 
 6.5† 69 
 7.6† 128 
 17.6‡
Plasma ALP (units/l)¶ 54 
 1.5‡ 71 
 8.7 45 
 3.1§ 33 
 3.8† 30 
 2† 81 
 7.2
Plasma glucagon (pg/ml)¶ 305 
 88 280 
 63 379 
 118 204 
 33 236 
 35 250 
 48
Plasma -hydroxyburate (nmol/l)* 0.62 
 0.07§ 0.85 
 0.05 0.84 
 0.04 0.58 
 0.06§ 0.61 
 0.05§ 0.56 
 0.05§
Data are means 
 SE. DIO mice were treated with recombinant murine FGF21 intraperitoneally at doses of 0 (vehicle), 0.1, 1, or 10 mg 
kg
1  day
1. An additional group of DIO mice was treated with rosiglitazone formulated in the high-fat diet to provide a dose of 4m g kg
1 
day
1. Mice on normal standard diet were included as controls and were injected intraperitoneally with vehicle. *,¶Measurements that were
conducted on day 42 (n  5/group) or day 24 (n  10/group) after the initiation of the treatments, respectively. ‡P  0.05, §P  0.01, †P  0.001
vs. vehicle-treated DIO mice.
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and substrate oxidation (respiratory quotient) by measur-
ing O2 consumption and CO2 production. Figure 5A shows
a biphasic circadian rhythm of O2 consumption typical for
the nocturnal habits of a rodent. We were able to detect a
statistically signiﬁcant increase in O2 consumption in DIO
mice treated with FGF21 on day 2 (Fig. 5A, arrow), and
this effect became progressively more evident as the
treatment continued. Associated with the increase in O2
consumption (Fig. 5A and B), CO2 production (Fig. 5C)
and physical activity (Fig. 5D) were also increased in mice
treated with FGF21. Energy expenditure was also in-
creased in FGF21-treated mice (Fig. 5E). The respiratory
quotient was not different between FGF21- and vehicle-
treated mice (Fig. 5F), suggesting that FGF21 does not
alter fuel selection between fatty acids and carbohydrate.
Recombinant FGF21 improves whole-body insulin
sensitivity and glucose metabolism. We performed a
2-h hyperinsulinemic-euglycemic clamp combined with
intravenous administration of [3-
3H]glucose and [1-
14C]2-
deoxyglucose in mice fed standard diet or high-fat diet for
15 weeks and treated with FGF21 or vehicle during the last
3 weeks of diet period. The basal (overnight-fasted) and
clamp glucose and insulin levels are shown in supplemen-
tary Table 1, available in the online appendix. Treatment
with 10 mg  kg
1  day
1 FGF21 restored the glucose
infusion rate to normal in DIO mice and further enhanced
insulin responsiveness in mice fed standard diet (Fig. 6A).
The improved insulin sensitivity was associated with re-
duced basal (Fig. 6B) and clamp hepatic glucose produc-
tion (HGP) (Fig. 6C) and increased whole-body glucose
turnover in FGF21-treated mice (Fig. 6D–F). The increased
glucose metabolism was reﬂected in signiﬁcantly elevated
whole-body glycogen plus lipid synthesis (Fig. 6F) and
modestly elevated whole-body glycolysis (Fig. 6E).
Tissue-speciﬁc glucose uptake was measured using
2-deoxyglucose during clamps. FGF21 treatment (10 mg 
kg
1  day
1) restored glucose uptake in skeletal muscle
and heart to normal levels in DIO mice (Fig. 7A and D).
Insulin-stimulated glucose uptake in white and brown
adipose tissue was enhanced in both standard diet– and
high-fat diet–fed mice after FGF21 treatment (Fig. 7B and
C), suggesting that these tissues were highly responsive to
FGF21. A dose level of 0.1 mg  kg
1  day
1 FGF21
increased glucose infusion rate (Fig. 6A), suppressed HGP
(Fig. 6C), and increased peripheral glucose uptake (Fig.
7A, C, and D) during clamp without reduction of body
weight (supplementary Table 1).
DISCUSSION
We administered recombinant murine FGF21 to DIO mice,
and we report that FGF21 corrects multiple metabolic
disorders in this model. We demonstrate that FGF21
reduces body weight, reverses hepatic steatosis, increases
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FIG. 3. Tissue histological analysis. Tissue sections were prepared at the end of the 6-week treatment period from mice fed standard diet and
treated with vehicle (A, E, I, and M) or fed high-fat diet and treated with vehicle (Vehi.; B, F, J, and N), FGF21 (10 mg  kg
1  day
1; C, G, K, and
O), or rosiglitazone (4m g kg
1  day
1; D, H, L, and P). H-E (A–D) and oil-red-O (E–H) staining of liver sections shows reversal of vacuolation
and lipid accumulation in FGF21-treated DIO mice. I–L: H-E staining of brown adipose tissue reveals the reduction of large lipid vacuoles in
FGF21-treated DIO mice. M–P: H-E staining of pancreatic sections shows the neutral effects of FGF21 on islet morphology (indicated by arrows).
(Please see http://dx.doi.org/10.2337/db08-0392 for a high-quality digital representation of this ﬁgure.)
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peripheral insulin sensitivity.
A moderate weight loss effect of recombinant FGF21
was observed in previous studies conducted in primates
(8) but not in obese rodents such as ob/ob mice or ZDF rats
(5). In contrast, we show that administration of recombi-
nant FGF21 led to dramatic body weight loss in DIO mice
without reducing food intake or causing apparent discom-
fort. Our data are in agreement with phenotypes of FGF21
transgenic mice, which are lean and resistant to high-fat
diet–induced obesity (5,9). The variable body weight re-
duction results among recombinant protein studies may lie
in the differences in FGF21 administration frequency, dose
levels, or animal models. We have found that FGF21-
induced body weight reduction is dose related. The dose
required to reduce adiposity (1 and 10 mg  kg
1  day
1)i s
higher that that required to improve insulin sensitivity and
glucose metabolism (0.1 mg  kg
1  day
1). Nevertheless,
FGF21 reduction of body weight appears not to be leptin
dependent because the same FGF21 doses resulted in
similar body weight reduction in ob/ob mice (data not
shown).
The antiobesity effect of FGF21 is to some extent
mediated by regulating energy metabolism. We show that
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DIABETES, VOL. 58, JANUARY 2009 255FGF21 stimulates whole-body energy expenditure and
increases metabolic rate and physical activity. Consistent
with the increased metabolic rate, administration of
FGF21 altered body composition, with a dramatic reduc-
tion in body fat mass and a small reduction in lean mass.
FGF21 appears to not change the preference in fatty acid
and carbohydrate utilization suggested by the unaltered
respiratory quotient. The reduced physical activity has
been shown to be a causative factor that accounts for 50%
of body weight gain in DIO rodents (20). FGF21 signiﬁ-
cantly increased locomotor activity levels, indicating the
importance of activity in FGF21-induced weight loss. This
observation is intriguing because FGF21 could be used as
an antiobesity agent, given that reduced spontaneous
physical activity and the resulting reduction of nonexer-
cise activity thermogenesis are critical factors contribut-
ing to the development of human obesity (21). Recently
reported data suggest that FGF21 administration in-
creased body temperature in DIO mice (22). Although we
did not measure body temperature, mice treated with
FGF21 had reduced lipid accumulation (Fig. 3K) and
increased levels of UCP-1 and -2 mRNA expression in
brown adipocytes (supplementary Fig. 1A). Therefore,
brown adipose tissue adaptive thermogenesis may have
also contributed to the enhanced whole-body energy
expenditure.
Interestingly, our ﬁndings appear to conﬂict with a
previous publication that indicated that FGF21 stimulates
torpor, reduces energy expenditure, and decreases physi-
cal activity (9). A signiﬁcant difference between the two
studies was that our energy metabolism study was con-
ducted in mice with free access to food, whereas the other
study was conducted in 24-h–fasted mice. The seemingly
divergent results suggest that the effect of FGF21 on
energy homeostasis may be subject to a feedback regula-
tion of nutritional and feeding status. The brain has been
A
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FIG. 5. Recombinant FGF21 increases energy expenditure and physical activity in DIO mice. Indirect calorimetry was conducted continuously for
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256 DIABETES, VOL. 58, JANUARY 2009recognized as a control center that integrates hormonal
and nutritional signals from the periphery and transmits
the control over feeding, energy expenditure, and physical
activity (23). Future studies will be needed to understand
whether FGF21 effects on energy metabolism involve a
central nervous system-associated mechanism.
FGF21 has previously been shown to lower blood
glucose levels in several diabetic rodent and monkey
models (5,8). Here, we show that FGF21 simultaneously
reduced plasma glucose and insulin levels in DIO mice
without causing fasting hypoglycemia, which is consistent
with what has been observed in other models (5). We
further demonstrate that the glucose-lowering effect of
FGF21 is linked with improved insulin sensitivity in sup-
pression of HGP and stimulation of peripheral glucose
uptake. FGF21 appears to play major roles in both insulin
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studies, we determined that a dose level of 0.1 mg  kg
1 
day
1 FGF21 did not reduce body weight and adiposity.
This dose was therefore speciﬁcally chosen for the hyper-
insulinemic-euglycemic clamp study on DIO mice so that
insulin sensitivity could be studied independently of body
weight and adiposity. We found that FGF21, at this dose
level, increased hepatic and peripheral insulin sensitivity,
reduced plasma levels of glucose and lipids, and restored
glucose tolerance. Therefore, FGF21-induced insulin sen-
sitivity is not secondary to body weight reduction. Al-
though understandably, reduced obesity further enhanced
insulin sensitivity as demonstrated with the high dose (10
mg  kg
1  day
1) of FGF21.
The insulin-sensitizing effect of FGF21 was also ob-
served in ob/ob mice, a model of more severe hyperglyce-
mia than the DIO mouse model (24). In that study, FGF21
restored insulin-mediated suppression of hepatic glucose
output and increased cardiac glucose uptake after 7 days
of treatment. Our hyperinsulinemic-euglycemic clamp
study was conducted in mice after 3 weeks of chronic
FGF21 treatment, and we observed improved insulin sen-
sitivity in multiple insulin-responsive tissues, including
liver, adipose tissue, skeletal muscle, and heart. FGF21
action requires a coreceptor, -klotho (11), which is
abundantly expressed in adipose tissues, readily detect-
able in liver, and insigniﬁcant in skeletal muscle and
perhaps the heart (supplementary Fig. 1C; 13). Based on
-klotho expression, FGF21 may act directly on liver and
adipose tissue and indirectly on skeletal muscle and heart.
This hypothesis is corroborated by the observation that
FGF21 improved hepatic and adipose tissue insulin sensi-
tivity irrespective of diet or disease state. In contrast, it
restored skeletal muscle and heart glucose uptake activity
only in mice fed high-fat diet and not standard diet. The
direct FGF21 action on liver and adipose tissue is possibly
mediated through induction of signaling transduction and
alteration in gene expression. It has been reported that
FGF21 induces FGF signaling and stimulates GLUT1 ex-
pression and glucose uptake in adipose tissue (5,25). We
have also observed reduced hepatic glucose-6-phospha-
tase and lipogenic gene expression and ameliorated hepa-
tosteatosis after FGF21 treatment. Such metabolic
changes would be expected to improve hepatic insulin
sensitivity and enhance insulin-mediated suppression of
HGP. The restored insulin sensitivity in skeletal muscle
and heart of FGF21-treated DIO mice could be a secondary
consequence of improved hepatic and adipose tissue func-
tions. As hepatosteatosis and adiposity were ameliorated
in DIO mice treated with FGF21, skeletal muscle triglyc-
eride contents were also reduced (Table 1). This reduction
of muscle fat accumulation is known to restore muscle
function and muscle insulin sensitivity (26).
FGF21 treatment resulted in striking improvement of
high-fat diet–induced hepatic steatosis. FGF21 has been
suggested to increase hepatic ketogenesis by mobilizing
adipocyte fatty acids to liver for oxidation (9). Surpris-
ingly, we were unable to ﬁnd evidence of increased
hepatic ketogenesis or adipose tissue lipolysis. The plasma
-hydroxybutyrate and free fatty acid levels were dose
dependently reduced in FGF21-treated DIO mice, which
argues against an increase in ketogenesis and lipolysis. It
is possible that our observed reduction in ketone bodies
and free fatty acid levels reﬂects a long-term effect of
FGF21 treatment after improved hepatic and adipose
tissue insulin sensitivity (27). Nevertheless, a recent hu-
man study indicated a lack of correlation between plasma
FGF21 concentration and ketone bodies, suggesting a
weak cause-effect relationship between FGF21 and keto-
genesis, at least in humans (28).
Here, we provide evidence that FGF21 reduces hepatic
steatosis by inhibiting nuclear SREBP-1 maturation and
therefore leads to reduced lipogenic gene expression and
possibly the rate of de novo fatty acid and triglyceride
synthesis. SREBP-1 is a transcription factor critical for
lipogenesis and is involved in the induction of hepatic
steatosis in several animal models (29,30). SREBP-1 is
synthesized as a membrane precursor form that requires
proteolytic cleavage to release its active NH2-terminal
transcription factor to translocate to the nucleus (31).
Treatment with FGF21 reduced the nuclear form of
SREBP-1 without affecting the amount of the precursor
protein or its mRNA, suggesting that FGF21 may inhibit
SREBP-1 proteolytic processing. FGF21 is a signaling
molecule acting through receptor-mediated kinase cas-
cades involving extracellular signal–related kinase-1/2 and
other typical FGF signaling pathways (5,14). How the
FGF21 signaling pathway affects SREBP-1 cleavage and
whether the regulation is mediated by SREBP cleavage-
activating protein and insulin-induced gene protein com-
plex are subjects for future investigation. Aberrant
induction of hepatic PPAR expression has also been
shown to contribute to hepatic steatosis in several insulin-
resistant models of obesity (32). In our experiments with
DIO mice, the hepatic expression of PPAR was increased.
Rosiglitazone further increased PPAR activity, as demon-
strated by increased expression of aP2 and CD36 and
worsened hepatic steatosis. In contrast, administration of
FGF21 reduced PPAR, aP2, and CD36 expression, which
may provide an additional mechanism for the observed
amelioration of hepatic steatosis.
In summary, our ﬁndings provide physiological and
molecular evidence that FGF21 reduces body weight,
plasma glucose, and lipid levels by regulating energy
homeostasis, hepatic glucose and lipid metabolism, and
insulin sensitivity.
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